Patents Examined by Rita J. Desai
  • Patent number: 11179376
    Abstract: The present invention provides salts of pyrazolo[1,5-?]pyridine derivative and use thereof. The invention also relates to a pharmaceutically acceptable composition comprising such salts and a method of using the salts and the pharmaceutically acceptable composition to prevent or treat a proliferative disorder or pulmonary fibrosis in a patient.
    Type: Grant
    Filed: December 15, 2018
    Date of Patent: November 23, 2021
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Mingming Sun
  • Patent number: 11180455
    Abstract: Provided herein are compounds that are useful in the treatment of pain in a subject.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: November 23, 2021
    Inventors: Thomas Andrew Wynn, Juan C. Alvarez, Demetri Theodore Moustakas, Markus Haeberlein, Lewis D. Pennington
  • Patent number: 11168097
    Abstract: The present technology relates generally cyclobutane boronates, including methods of preparation by exposing a mixture of a compound of Formula I in a solvent and a catalytic amount of a visible light sensitizer to provide a compound of Formula II, stereoisomers thereof, and/or salts of any of the foregoing. The cyclobutane boronate compounds are useful intermediates in the preparation of pharmaceutically active compounds as well as other useful compounds.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 9, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Tehshik Peter Yoon, Spencer Owen Scholz, Rowan Mark Littlefield, Niecia Elizabeth Flikweert
  • Patent number: 11161818
    Abstract: A novel quinolone derivative and methods of its preparation are described in which the novel derivative comprises a diphenyl ether substituent on the nitrogen atom at the 1-position of the main quinolone ring. The novel derivative is shown to have antibacterial and anti-tumor cell activity.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: November 2, 2021
    Assignee: HANGZHOU NORMAL UNIVERSITY
    Inventors: Pengfei Zhang, Wanmei Li, Weiming Xu, Haifeng Wu
  • Patent number: 11149017
    Abstract: Disclosed are solid state forms of Apalutamide and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: October 19, 2021
    Assignee: WATSON LABORATORIES INC.
    Inventors: Anantha Rajmohan Muthusamy, Sundara Lakshmi Kanniah, Nitin Dnyaneshwar Arote, Omkar Vilas Bhagwat, Jitendra Kamalakar Sonar, Vitthal Baburao Poundkar, Yogesh Dhananjay Wagh
  • Patent number: 11142503
    Abstract: The invention provides (1) processes for making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; (2) compositions useful in making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: October 12, 2021
    Assignee: YALE UNIVERSITY
    Inventors: Seth Herzon, Maung Kyaw Moe Tun
  • Patent number: 11135206
    Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: October 5, 2021
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo
  • Patent number: 11098071
    Abstract: The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 24, 2021
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Xin Xie, Linhai Chen, Qing Zhang, Yufeng Xiao, Hui Yang
  • Patent number: 11096930
    Abstract: Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: August 24, 2021
    Assignees: Merck Sharp & Dohme Corp., IOmet Pharma Ltd.
    Inventors: Phillip M. Cowley, Meredeth Ann McGowan, Thomas J. Brown, Yongxin Han, Kun Liu, Qinglin Pu, Alan Wise, Hongjun Zhang, Hua Zhou
  • Patent number: 11098052
    Abstract: The present disclosure relates to 4-azapodophylotoxins compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 24, 2021
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventor: George Robert Pettit
  • Patent number: 11091438
    Abstract: The present invention provides processes for the preparation of diverse heterocyclic scaffolds from alpha-enaminone building bloc of formula (I).
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: August 17, 2021
    Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
    Inventor: Dmitry Tsvelikhovsky
  • Patent number: 11091451
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 17, 2021
    Assignee: RAZE THERAPEUTICS, INC.
    Inventor: Nello Mainolfi
  • Patent number: 11084804
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 10, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Matthew M. Hamilton, Mark Miller, Peter D. J. Grootenhuis
  • Patent number: 11084789
    Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders associated with mast cells. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more diseases and disorders associated with mast cells.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: August 10, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Lijun Sun, Aristidis Veves
  • Patent number: 11084812
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: August 10, 2021
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • Patent number: 11066402
    Abstract: The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: July 20, 2021
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. V. S. Vakkalanka, Dhanapalan Nagarathnam, Srikant Viswanadha, Meyyappan Muthuppalaniappan, Govindarajulu Babu, Prashant K. Bhavar
  • Patent number: 11059823
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tatiana Koudriakova, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Russell C. Smith, Mark S. Tichenor, Aihua Wang
  • Patent number: 11052080
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: July 6, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • Patent number: 11053261
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: July 6, 2021
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Martin Valik, Roman Gabriel, Pavel Vraspir, David Lukas
  • Patent number: 11052072
    Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: July 6, 2021
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo